"In 2021, greater functional limitation (PCFS ≥ 2) was associated with a higher burden of persistent cardiorespiratory and neurocognitive symptoms (Supplementary Table S14).\n\nIn the multivariable model of persistent symptoms in 2021 (Table 2), chest tightness (aOR, 6.18; 95% CI 2.55–14.98), depressive symptoms (aOR, 5.81; 95% CI 2.46–13.69), resting dyspnea (aOR, 4.09; 95% CI 1.89–8.83), anxiety disorder (aOR, 4.05; 95% CI 1.71–9.58), joint pain (aOR, 2.85; 95% CI 1.48–5.47), back pain (aOR, 2.45; 95% CI 1.09–5.50), fatigue (aOR, 2.36; 95% CI 1.24–4.48), hypertension (aOR, 2.25; 95% CI 1.12–4.52), dyspnea on exertion (aOR, 2.17; 95% CI 1.16–4.04), memory impairment (aOR, 2.15; 95% CI 1.20–3.85), and sleep disorder (aOR, 2.04; 95% CI 1.11–3.75) were associated with greater functional limitation. No effect of demographic factors, including age, sex, and obesity, was observed after adjustment (Table 2).\n\nTable 2 Final Multivariable Logistic Regression Models of Associations Between Persistent Symptoms and Functional Limitation (PCFS ≥ 2), 2021 and 2024."